Abstract: Neuroinflammation driven by microglia is a central pathological feature across various neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), prion diseases, and glaucoma. PLX5622 has emerged as a highly selective, brain-penetrant colony-stimulating factor 1 receptor (CSF1R) inhibitor capable of depleting up to 99% of microglia in the central nervous system. This comprehensive literature review explores the pharmacological activity, molecular mechanisms, and structure-activity relationships of PLX5622 in the context of neurodegeneration. While PLX5622-mediated microglial depletion demonstrates significant neuroprotective effects in AD, PD, and traumatic brain injury by reducing neuroinflammation and toxic protein accumulation, it exacerbates pathology in conditions like prion disease and ocular hypertension-dependent glaucoma, where microglia play a crucial protective role. Furthermore, the review highlights current limitations, such as peripheral immune suppression and sex-dependent variability, and discusses future perspectives, including microglial repopulation strategies to reset the neuroinflammatory environment.
1. Introduction
Neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), represent a growing global health burden characterized by progressive neuronal loss and cognitive or motor decline [1]. A common hallmark across these disorders is chronic neuroinflammation, primarily mediated by microglia, the resident immune cells of the central nervous system (CNS) [1][2]. While microglia are essential for maintaining brain homeostasis, synaptic pruning, and immune surveillance, they can adopt aberrant, pro-inflammatory phenotypes in chronic disease states, exacerbating neurodegeneration [1][6].
Microglial survival, proliferation, and differentiation are critically dependent on signaling through the colony-stimulating factor 1 receptor (CSF1R) [1][4]. Consequently, pharmacological inhibition of CSF1R has become a primary strategy to study microglial function and therapeutic potential. PLX5622 is a highly specific, orally bioavailable CSF1R inhibitor that can cross the blood-brain barrier (BBB) and effectively deplete the microglial population in the brain [4][6]. By utilizing PLX5622, researchers have been able to investigate the dual roles of microglia—both protective and detrimental—across various neurodegenerative and neuroinflammatory conditions [1][3].
2. Pharmacological Activity
The pharmacological effects of PLX5622 vary significantly depending on the specific neurodegenerative disease model, the timing of administration, and the duration of treatment.
Alzheimer's Disease (AD): In AD models (e.g., 5xFAD, 3xTg, and APP/PS1 mice), PLX5622 treatment generally yields beneficial outcomes. Microglial depletion has been shown to reduce neuroinflammation, decrease amyloid-beta (Aβ) plaque formation, and mitigate tau pathology [1]. For instance, PLX5622-induced depletion reduced AT8+ phosphorylated tau by 86% in the granular layer of tauopathy models and prevented the downregulation of synaptic genes [4]. Furthermore, it has been associated with improvements in cognitive behavior [1].
Parkinson's Disease (PD): In PD models, PLX5622 demonstrates neuroprotective effects when administered prior to or during disease induction. It reduces α-synuclein accumulation and protects dopaminergic neurons in the substantia nigra [1]. However, short-term depletion protocols (e.g., 3-5 weeks) have occasionally been linked to detrimental effects, including worsened motor impairments, indicating that the timing and duration of depletion are critical [1].
Prion Disease: Conversely, in prion diseases, microglia play a vital host-defense role. Treatment with PLX5622 to ablate microglia significantly accelerated prion disease progression, increased the accumulation of protease-resistant prion protein (PrPSc), and shortened the lifespan of infected mice by 20 to 33 days [5]. This indicates that microglia are beneficial and necessary for clearing PrPSc during prion infection [5].
Glaucoma and Ocular Hypertension: In the D2 mouse model of age-related ocular hypertension (OHT), PLX5622-mediated microglial depletion exacerbated glaucomatous neurodegeneration. Depletion led to a significant increase in severe optic nerve damage and retinal ganglion cell (RGC) soma loss, demonstrating that microglia serve a critical neuroprotective function during OHT pathogenesis [3].
Traumatic Brain Injury (TBI): In TBI models, PLX5622 effectively attenuates neuroinflammation and oxidative stress. Depletion of microglia reversed TBI-induced inflammatory gene expression and reduced reactive oxygen species (ROS) production, thereby minimizing neuronal damage and behavioral deficits [6].
Microglial Repopulation: A unique pharmacological feature of PLX5622 is that its withdrawal allows for rapid microglial repopulation within 5 to 21 days [6]. Repopulated microglia often adopt a non-inflammatory, homeostatic phenotype, which has shown therapeutic promise in resetting the neuroinflammatory environment in both AD and PD models [1][6].
3. Molecular Mechanism of Action
PLX5622 functions as a potent and selective tyrosine kinase inhibitor targeting the CSF1R [4]. Under normal physiological conditions, CSF1R interacts with its ligands, Colony-Stimulating Factor 1 (CSF-1) and Interleukin-34 (IL-34), promoting phosphorylation at multiple tyrosine residues within its cytoplasmic domain. This signaling cascade is essential for the survival, proliferation, and differentiation of microglia [5][6].
By competitively binding to the receptor, PLX5622 blocks the tyrosine kinase-dependent activation of CSF1R. The cessation of this critical survival signaling pathway leads to the rapid elimination of microglia from the CNS via apoptosis, specifically through the activation of Caspase-3 [1][5]. PLX5622 is typically administered orally via rodent chow (commonly at 1200 mg/kg), where it efficiently crosses the BBB to achieve up to 99% depletion of microglia within a few days of treatment [4][6].
4. Structure-Activity Relationship (SAR)
PLX5622 was developed to improve upon the selectivity and pharmacokinetic profile of earlier CSF1R inhibitors, such as PLX3397 (Pexidartinib) and GW2580 [4][6]. While chemically related to PLX3397, PLX5622 exhibits a significantly refined structure-activity profile.
The most notable SAR improvement is its enhanced selectivity for CSF1R over other receptor tyrosine kinases, particularly c-kit. PLX5622 has an IC50 of 0.016 μM for CSF1R, which is comparable to PLX3397 (0.017 μM). However, PLX5622 has a drastically reduced inhibitory potential against c-kit, with an IC50 of 0.86 μM, making it more than 50 times more selective against c-kit compared to PLX3397 (IC50 for c-kit = 0.012 μM) [4]. Furthermore, the structural modifications in PLX5622 grant it superior brain penetrance compared to PLX3397 and other earlier inhibitors, allowing for highly efficient microglial depletion in the CNS without requiring excessively high systemic doses [4][6].
5. Current Limitations
Despite its efficacy as a research tool, the use of PLX5622 presents several limitations:
Peripheral and Off-Target Effects: Although highly selective for the CNS, PLX5622 still impacts peripheral immune cells that rely on CSF1R. It suppresses bone marrow-derived macrophages, C-C chemokine receptor type 2 (CCR2+) monocyte progenitors, and CX3CR1+ macrophages, which can impair peripheral immune responses and wound healing [3][4].
Disease-Specific Detrimental Outcomes: Broad microglial depletion is not universally beneficial. In diseases where microglia actively clear toxic aggregates or protect neurons—such as in prion diseases and ocular hypertension-dependent glaucoma—PLX5622 treatment exacerbates neurodegeneration and accelerates disease progression [3][5].
Developmental Toxicity: PLX5622 cannot be safely used during gestation or early neonatal periods. Administration during these times leads to severe developmental defects, including craniofacial deformities, weight loss, and abnormal neural circuit establishment due to the disruption of microglial roles in synaptic pruning [4].
Experimental Heterogeneity and Sex Differences: Preclinical studies show high variability based on dosage, treatment duration, and the timing of intervention relative to disease onset. Additionally, biological sex significantly modulates the efficacy of PLX5622; male mice often exhibit higher depletion rates and different behavioral outcomes compared to females under identical dosing regimens [1].
6. Future Perspectives
The future of PLX5622 and CSF1R inhibitors in neurodegenerative disease research lies in refining their application to maximize therapeutic benefits while minimizing adverse effects.
Repopulation Strategies: Instead of chronic depletion, transient or intermittent depletion followed by drug withdrawal ("deplete and repeat") is a highly promising avenue. This allows the CNS to be repopulated with new, homeostatic microglia, effectively resetting the neuroinflammatory environment without the risks of long-term immunosuppression [1][6].
Targeted Delivery and Specificity: To circumvent peripheral immune suppression, future research should explore central routes of administration (e.g., intrathecal or intracerebral delivery) or the development of next-generation inhibitors that are exclusively active within the CNS [1].
Standardization and Clinical Translation: There is a critical need for standardized preclinical protocols that account for sex differences, parent-of-origin genetic effects, and post-disease onset interventions. Understanding the precise temporal window in which microglia transition from protective to detrimental will be essential for translating CSF1R inhibition from rodent models to human clinical trials for diseases like AD and PD [1].
